Survival following the documentation of platinum and taxane resistance in ovarian cancer: A single institution experience involving multiple phase 2 clinical trials

Gynecologic Oncology

Volumn 93, Issue 3, 2004, Pages 699-701

  Markman, Maurie ^a,b   Webster, Kenneth ^a   Zanotti, Kristine ^a   Peterson, Gertrude ^a   Kulp, Barbara ^a   Belinson, Jerome ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ovarian cancer; Platinum chemotherapy; Platinum resistant ovarian cancer; Taxane chemotherapy

Indexed keywords

DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GEMCITABINE; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THERAPY RESISTANCE; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 2942679356     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.023     Document Type: Article

References (10)

1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334:1996;1-6
2. Muggia F.M., Braly P.S., Brady M.F., Sutton G., Niemann T.H., Lentz D.L., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 18:2000;106-115
3. Markman M. Optimizing primary chemotherapy in ovarian cancer. Hematol. Oncol. Clin. North Am. 17:2003;957-968
4. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21:2003;3194-3200
5. Markman M., Bookman M.A. Second-line treatment of ovarian cancer. The Oncologist. 5:2000;26-35
6. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum-and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79:2000;116-119
7. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78:2000;369-372
8. Markman M., Webster K., Zanotti K., Kulp B., Peterson G., Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol. Oncol. 90:2003;593-596
9. Markman M., Zanotti K., Webster K., Peterson G., Kulp B., Belinson J. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol. Oncol. 91:2003;573-576
10. Markman M., Belinson J., Webster K., Zanotti K., Borden E., Morrison B., et al. Phase 2 trial of interferon beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum. Oncology. 2004;. (in press)